In an ongoing legal controversy over cancer drug patents, Japanese pharmaceutical firm Daiichi Sankyo is urging a Seattle federal judge not to dismiss an arbitral award rejecting the claims of American biotechnology company, Seagen Inc. Daiichi Sankyo contends that Seagen’s attempt to vacate the ruling, which pertains to a dispute involving billions of dollars, is ill-founded.
The patent dispute revolves around Seagen’s claims for a substantial compensation, touted to be in billions. However, according to the established arbitral decision, these claims have been thwarted, a stance that Daiichi Sankyo passionately upholds. The Japanese drug giant is presently seeking legal validation of the said arbitrator’s award against Seagen from the Seattle federal court.
For more details on the unfolding case, the court and all parties involved are tracked on Law360.